Quick Answer
Iterum Therapeutics plc reported Diluted EPS of $1.26 per share (loss) for fiscal year 2024.
Iterum Therapeutics plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$1.26 | +57.4% |
| 2023 | -$2.96 | +18.5% |
| 2022 | -$3.63 | +56.8% |
| 2021 | -$8.41 | +74.1% |
| 2020 | -$32.49 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.20 | +33.3% | -25.0% |
| June 30, 2025 | -$0.16 | +46.7% | -14.3% |
| March 31, 2025 | -$0.14 | +69.6% | +53.3% |
| September 30, 2024 | -$0.30 | +0.0% | +0.0% |
| June 30, 2024 | -$0.30 | +68.4% | +34.8% |
| March 31, 2024 | -$0.46 | +41.0% | -53.3% |
| September 30, 2023 | -$0.30 | +87.4% | +68.4% |
| June 30, 2023 | -$0.95 | -72.7% | -21.8% |
- Iterum Therapeutics plc showed an increase of +57.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, Iterum Therapeutics plc’s diluted eps has grown by 96.1% (from $32.49 per share (loss) to $1.26 per share (loss)).
- The most recent figure is from Iterum Therapeutics plc’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: